India purchases the most COVID-19 vaccines amongst other countries
India has purchased 1.6 billion doses of COVID-19 vaccines, the most amount compared to other countries, according to a global analysis.
With India’s influence in manufacturing vaccines, they have purchased 500 million doses of the Oxford University-AstraZeneca vaccine candidate, one billion from the American company Novavax and 100 million doses of the Sputnik-V candidate from Russia’s Gamaleya Research Institute.
India hopes to utilize the 1.6 billion doses they have purchased to provide immunization of up to 800 million people, 60 percent of its total population. It is said that an estimate of 400 million to 500 million doses of COVID-19 vaccines would be accessible to 250 million to 300 million of its population by July to August 2021.
Canadian Government Approves Pfizer-BioNTech COVID-19 Vaccines
On December 9, Canada has approved its first COVID-19 vaccines and will commence delivering and administering the first shots in the following week across the country.
According to the plan, Canada is now in a good position to immunize 100 percent of the population in the year 2021. In a different table, the immunization could be completed by the end of September.
Canada has a firm order for 20 million doses of the Pfizer-BioNTech COVID-19 vaccine, which is enough to vaccinate 10 million people. The country also has an option to buy up to 56 million more of the vaccine. Pfizer will deliver its vaccine, which requires ultra-cold storage, to warehouses across the country.
According to federal guidelines, the first people to receive the vaccinations include some healthcare workers, long-term care residents and employees, the elderly and Indigenous populations.
Israel receives their first delivery of Pfizer COVID-19 vaccines.
Israel received its first orders of Pfizer’s COVID-19 vaccines on December 9. This delivery was the first of 8 million doses ordered from US pharmaceutical giant Pfizer-BioNTech.
The vaccine from Pfizer has yet to acquire the needed regulatory approvals to be used in Israel. However, Israel’s prime minister states that the vaccine will receive approval soon.
According to results of the third-phase clinical trials has revealed that the vaccine was 90 percent effective in preventing COVID-19 symptoms and did not create any negative side effects among thousands of volunteers.